Related Posts

• 
  The FDA is Listening: Integrating the Voice of the Patient in Drug Development for Parkinson’s and Huntington’s Diseases
• 
  The Critical Path for Parkinson’s Consortium: Understanding Motor Disease Progression Through Quantitative Medicine
• 
  Global Regulatory Agencies Support the Use of Dopamine Transporter Neuroimaging for Subject Selection in Clinical Trials Targeting Early Stage Parkinson’s Disease
• 
  Critical Path for Parkinson’s: Regulatory Path to Enable Targeting the Right Patients in Clinical Trials of Early Stages of Parkinson’s Disease
• 
  CAMD: Development of Therapeutic Area-Specific Data Standards for Alzheimer’s and Parkinson’s Patients